戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tory findings were similar for children with oligoarticular and polyarticular disease, differences in
2 onset PsJIA bear similarities to early-onset oligoarticular and polyarticular JIA patients, including
3 tibility in Finnish patients with persistent oligoarticular and polyarticular rheumatoid factor (RF)-
4  (JIA), comprising the most common subtypes (oligoarticular and rheumatoid factor-negative polyarticu
5  be an effective treatment for both extended oligoarticular and systemic JIA in this shortterm trial.
6                              In the extended oligoarticular arthritis group, MTX treatment produced s
7 eumatology criteria for systemic or extended oligoarticular arthritis were eligible for this multicen
8  patients with systemic and 43 with extended oligoarticular arthritis were enrolled.
9 n late-stage complication of this disease is oligoarticular arthritis, often involving the knee.
10 eripheral joints (most commonly knees) in an oligoarticular, asymmetric fashion; inflammation at tend
11 polyarticular, but not those with persistent oligoarticular, disease (P = 0.06, OR 2.9 [95% CI 0.9-9.
12 children, although joint involvement remains oligoarticular in the majority of children.
13 cantly lower in patients with extended-to-be oligoarticular JIA (0.57 compared with 0.90 in the persi
14  T cells, which was a significant feature of oligoarticular JIA (n = 62) as compared to polyarticular
15 rts [219 systemic JIA (sJIA), 187 persistent oligoarticular JIA (pOJIA), and 139 extended OJIA (eOJIA
16 o were employed (P = 0.03) and in those with oligoarticular JIA (t = 2.29, P = 0.02).
17 ples from patients with early- or late-onset oligoarticular JIA (with 97% accuracy) or from patients
18 o DRB1 and was similar between patients with oligoarticular JIA and a younger subgroup of patients wi
19 jor classifier of samples from patients with oligoarticular JIA and patients with polyarticular JIA.
20  HLA-DRB1*1103/1104, found in the group with oligoarticular JIA and the group of younger patients wit
21 ubtypes (P = 0.0097); children with extended oligoarticular JIA had the longest interval (median 60 w
22 ch to predict the likelihood of extension of oligoarticular JIA to a more severe disease phenotype.
23 tive systemic JIA and 9 with active extended oligoarticular JIA was assessed by real-time polymerase
24                   Patients with recent-onset oligoarticular JIA were identified and grouped according
25 edication (5%), and patients with persistent oligoarticular JIA were the most likely (68%).
26 scovery rate 5%) in PBMCs from children with oligoarticular JIA whose disease began before age 6 year
27 n 101 patients with JIA (79% female; 24 with oligoarticular JIA, 40 with polyarticular JIA, 18 with s
28 ts with recent-onset JIA (39 with persistent oligoarticular JIA, 45 with rheumatoid factor-negative p
29 .5 (95% CI 1.9-6.5) in those with persistent oligoarticular JIA, and 4.1 (95% CI 2.5-6.7) in those wi
30               Among patients with persistent oligoarticular JIA, most of the disease course was chara
31             Also in contrast to findings for oligoarticular JIA, patients with polyarticular arthriti
32 al fluid samples obtained from children with oligoarticular JIA, polyarticular JIA, or systemic JIA w
33 3 and C12orf30 variants were associated with oligoarticular JIA, while the STAT4 variant was associat
34 matoid factor-negative polyarticular JIA and oligoarticular JIA.
35           Uveitis is most common in extended oligoarticular JIA.
36 ular juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis
37 or negative for rheumatoid factor), extended oligoarticular juvenile idiopathic arthritis, enthesitis
38 ral blood (PB) T cells from 20 patients with oligoarticular- or polyarticular-onset JIA.
39 , sera and synovial fluid from children with oligoarticular, polyarticular, or systemic-onset JRA wer
40                                Patients with oligoarticular PsA cannot be accurately assessed for act
41  compared to the known IFN-mediated extended oligoarticular subtype.
42 randomising centre and pattern of arthritis (oligoarticular vs polyarticular).